Loading…
Lobbying Spend
—
Filings
60
Firms Hired
3
Active Period
2015–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Improving Patient Access to Care and Treatment Act
2022 · fourth_quarter · Firm: STANTON PARK GROUP
HR 5950 and S 3257, the Improving Patient Access to Care and Treatment Act. Reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: — · Firm income: $5,000
Matched citations: HR 5950
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
2022 · fourth_quarter · Firm: STANTON PARK GROUP
HR 5950 and S 3257, the Improving Patient Access to Care and Treatment Act. Reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: — · Firm income: $5,000
Matched citations: S 3257
Improving Patient Access to Care and Treatment Act
2022 · fourth_quarter · Firm: STANTON PARK GROUP
HR 5950 and S 3257, the Improving Patient Access to Care and Treatment Act. Reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: — · Firm income: —
Matched citations: HR 5950
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
2022 · fourth_quarter · Firm: STANTON PARK GROUP
HR 5950 and S 3257, the Improving Patient Access to Care and Treatment Act. Reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: — · Firm income: —
Matched citations: S 3257
Fairness in Orphan Drug Exclusivity Act
2022 · first_quarter · Firm: STANTON PARK GROUP
HCR - HR 1629 To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs; S. 250 Fairness in Orphan Drug Exclusivity Act; reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: — · Firm income: —
Matched citations: HR 1629
Fairness in Orphan Drug Exclusivity Act
2022 · first_quarter · Firm: STANTON PARK GROUP
HCR - HR 1629 To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs; S. 250 Fairness in Orphan Drug Exclusivity Act; reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: — · Firm income: —
Matched citations: S. 250
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: STANTON PARK GROUP
HCR - HR 1629 To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs; S. 250 Fairness in Orphan Drug Exclusivity Act; reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: — · Firm income: $50,000
Matched citations: HR 1629
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: STANTON PARK GROUP
HCR - HR 1629 To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs; S. 250 Fairness in Orphan Drug Exclusivity Act; reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: — · Firm income: $50,000
Matched citations: S. 250
Fairness in Orphan Drug Exclusivity Act
2021 · third_quarter · Firm: STANTON PARK GROUP
HCR - HR 1629 To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs; S. 250 Fairness in Orphan Drug Exclusivity Act; reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: — · Firm income: $50,000
Matched citations: HR 1629
Fairness in Orphan Drug Exclusivity Act
2021 · third_quarter · Firm: STANTON PARK GROUP
HCR - HR 1629 To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs; S. 250 Fairness in Orphan Drug Exclusivity Act; reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: — · Firm income: $50,000
Matched citations: S. 250
Fairness in Orphan Drug Exclusivity Act
2021 · second_quarter · Firm: STANTON PARK GROUP
HCR - HR 1629 To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs; S. 250 Fairness in Orphan Drug Exclusivity Act; reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: — · Firm income: $50,000
Matched citations: HR 1629
Fairness in Orphan Drug Exclusivity Act
2021 · second_quarter · Firm: STANTON PARK GROUP
HCR - HR 1629 To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs; S. 250 Fairness in Orphan Drug Exclusivity Act; reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: — · Firm income: $50,000
Matched citations: S. 250
Fairness in Orphan Drug Exclusivity Act
2021 · first_quarter · Firm: STANTON PARK GROUP
HCR - HR 1629 To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs; S. 250 Fairness in Orphan Drug Exclusivity Act; reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: — · Firm income: $50,000
Matched citations: HR 1629
Fairness in Orphan Drug Exclusivity Act
2021 · first_quarter · Firm: STANTON PARK GROUP
HCR - HR 1629 To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs; S. 250 Fairness in Orphan Drug Exclusivity Act; reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: — · Firm income: $50,000
Matched citations: S. 250
Fairness in Orphan Drug Exclusivity Act
2020 · fourth_quarter · Firm: STANTON PARK GROUP
reducing stigma and promoting treatment of opioid use disorder raising awareness of the benefits of medication assisted therapy (MAT) ensuring patient access to MAT FDA approval and exclusivity process HR 4712 Fairness in Orphan Drug Exclusivity Act S 3271 Fairness in Orphan Drug Exclusivity Act patient access to practitioner-administered therapies
Client expense: — · Firm income: $50,000
Matched citations: HR 4712
Fairness in Orphan Drug Exclusivity Act
2020 · fourth_quarter · Firm: STANTON PARK GROUP
reducing stigma and promoting treatment of opioid use disorder raising awareness of the benefits of medication assisted therapy (MAT) ensuring patient access to MAT FDA approval and exclusivity process HR 4712 Fairness in Orphan Drug Exclusivity Act S 3271 Fairness in Orphan Drug Exclusivity Act patient access to practitioner-administered therapies
Client expense: — · Firm income: $50,000
Matched citations: S 3271
Fairness in Orphan Drug Exclusivity Act
2020 · third_quarter · Firm: STANTON PARK GROUP
reducing stigma and promoting treatment of opioid use disorder raising awareness of the benefits of medication assisted therapy (MAT) ensuring patient access to MAT FDA approval and exclusivity process HR 4712 Fairness in Orphan Drug Exclusivity Act S 3271 Fairness in Orphan Drug Exclusivity Act patient access to practitioner-administered therapies
Client expense: — · Firm income: $50,000
Matched citations: HR 4712
Fairness in Orphan Drug Exclusivity Act
2020 · third_quarter · Firm: STANTON PARK GROUP
reducing stigma and promoting treatment of opioid use disorder raising awareness of the benefits of medication assisted therapy (MAT) ensuring patient access to MAT FDA approval and exclusivity process HR 4712 Fairness in Orphan Drug Exclusivity Act S 3271 Fairness in Orphan Drug Exclusivity Act patient access to practitioner-administered therapies
Client expense: — · Firm income: $50,000
Matched citations: S 3271
Fairness in Orphan Drug Exclusivity Act
2020 · second_quarter · Firm: STANTON PARK GROUP
reducing stigma and promoting treatment of opioid use disorder raising awareness of the benefits of medication assisted therapy (MAT) ensuring patient access to MAT FDA approval and exclusivity process HR 4712 Fairness in Orphan Drug Exclusivity Act S 3271 Fairness in Orphan Drug Exclusivity Act patient access to practitioner-administered therapies
Client expense: — · Firm income: $50,000
Matched citations: HR 4712
Fairness in Orphan Drug Exclusivity Act
2020 · second_quarter · Firm: STANTON PARK GROUP
reducing stigma and promoting treatment of opioid use disorder raising awareness of the benefits of medication assisted therapy (MAT) ensuring patient access to MAT FDA approval and exclusivity process HR 4712 Fairness in Orphan Drug Exclusivity Act S 3271 Fairness in Orphan Drug Exclusivity Act patient access to practitioner-administered therapies
Client expense: — · Firm income: $50,000
Matched citations: S 3271
Fairness in Orphan Drug Exclusivity Act
2020 · first_quarter · Firm: STANTON PARK GROUP
reducing stigma and promoting treatment of opioid use disorder raising awareness of the benefits of medication assisted therapy (MAT) ensuring patient access to MAT FDA approval and exclusivity process HR 4712 Fairness in Orphan Drug Exclusivity Act
Client expense: — · Firm income: $50,000
Matched citations: HR 4712
Fairness in Orphan Drug Exclusivity Act
2019 · fourth_quarter · Firm: STANTON PARK GROUP
reducing stigma and promoting treatment of opioid use disorder raising awareness of the benefits of medication assisted therapy (MAT) ensuring patient access to MAT FDA approval and exclusivity process HR 4712 Fairness in Orphan Drug Exclusivity Act
Client expense: — · Firm income: $50,000
Matched citations: HR 4712
Preventing Overdoses While in Emergency Rooms Act of 2018
2018 · fourth_quarter · Firm: STANTON PARK GROUP
reducing stigma and promoting treatment of opioid use disorder raising awareness of the benefits of medication assisted therapy (MAT) ensuring patient access to MAT, including S.916- Protecting Patient Access to Emergency Medications Act of 2017; HR 5202, Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018; and HR 5176, Preventing Overdoses While in Emergency Rooms Act of 2018 HR 6, "Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act"
Client expense: — · Firm income: $50,000
Matched citations: HR 5176
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
2018 · fourth_quarter · Firm: STANTON PARK GROUP
reducing stigma and promoting treatment of opioid use disorder raising awareness of the benefits of medication assisted therapy (MAT) ensuring patient access to MAT, including S.916- Protecting Patient Access to Emergency Medications Act of 2017; HR 5202, Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018; and HR 5176, Preventing Overdoses While in Emergency Rooms Act of 2018 HR 6, "Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act"
Client expense: — · Firm income: $50,000
Matched citations: HR 5202
SUPPORT for Patients and Communities Act
2018 · fourth_quarter · Firm: STANTON PARK GROUP
reducing stigma and promoting treatment of opioid use disorder raising awareness of the benefits of medication assisted therapy (MAT) ensuring patient access to MAT, including S.916- Protecting Patient Access to Emergency Medications Act of 2017; HR 5202, Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018; and HR 5176, Preventing Overdoses While in Emergency Rooms Act of 2018 HR 6, "Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act"
Client expense: — · Firm income: $50,000
Matched citations: HR 6
Source: Senate LDA